fig2
![Endocrine therapy in metastatic breast cancer-more than just CDK4/6 inhibitors](https://image.oaes.cc/33c22a8e-b6b7-4c3e-aba8-8630b16b9c45/5447.fig.2.jpg)
Figure 2. Targeting the PI3K/AKT/mTOR pathway; Modified from Du Rusquec et al., 2020[69]. E: Estrogen; ER: estrogen receptor; GFR: growth factor receptor; PI3K: phosphatidylinositol-3 kinase; PI3Ki: phosphatidylinositol-3 kinase inhibitor; AKT: protein kinase B; AKTi: AKT kinase inhibitor; PTEN: phosphatase and tensin homolog; mTORC1/2: mammalian target of rapamycin complex 1/2; mTORC1/2i: mammalian target of rapamycin complex 1/2 inhibitor.